Simple Summary In hematologic cancers, Minimal Residual Disease (MRD) monitoring,
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …

The t (8; 21) abnormality occurs in a minority of acute myeloid leukemia (AML) patients. The
translocation results in an in‐frame fusion of two genes, resulting in a fusion protein of one N …

We have used a mass spectrometry-based proteomic approach to compile an atlas of the
thermal stability of 48,000 proteins across 13 species ranging from archaea to humans and …

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph+ acute
lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 …

The Wnt signaling pathway is essential in the development and homeostasis of blood and
immune cells, but its exact role is still controversial and is the subject of intense research …

Laboratory diagnostics in patients with a hematological malignancy has three major
applications: establishing the diagnosis, prognostic classification and evaluation of …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

The process of malignant transformation in paediatric acute leukaemias is complex,
requiring at least two deleterious events resulting in DNA damage. This damage ranges …

Measurement of submicroscopic (minimal) levels of residual disease (MRD) can be used to
monitor treatment response much more precisely than morphological screening of bone …

Purpose: To develop a novel diagnostic method for the assessment of drug efficacy in
chronic myeloid leukemia (CML) patients individually, we generated a biosensor that …